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Simultaneous hemodynamic and radionuclide anglo-
graphic assessment was made at rest and during exercise
in nine patients with severe chronic congestive heart
failure to determine the value of radionuclide left ven-
tricular ejection fraction measurement in predicting the
hemodynamic response to short-term treatment with oral
hydralazine. Hydralazine, 50 to 100 mg orally every 6
hours, produced significant increases in cardiac index
and stroke volume index at rest and during exercise (p
< 0.01) and in left ventricular stroke work index at rest
(p < 0.01) and during exercise (p < 0.05), significant
decreases in systemic vascular resistance at rest and dur-
ing exercise (p < 0.01) and significant increases in radio-
nuclide angiographic left ventricular ejection fraction at
rest (control 0.21 ± 0.06 vs. hydralazine 0.26 ± 0.07,
P < 0.01) and during exercise (control 0.21 ± 0.08 vs.
hydralazine 0.24 ± 0.09, p < 0.05). However, there
were no statistically significant correlations between
Various vasodilator agents have been demonstrated to produce
beneficial hemodynamic responses in patients with chronic
congestive heart failure. In particular, hydralazine, a vas-
odilator agent that acts predominantly on the arterial bed,
increases cardiac output and decreases systemic vascular
resistance both at rest and during exercise in patients with
heart failure (1-6). Currently, evaluation of the hemody-
namic effects of hydralazine therapy in patients with heart
failure requires invasive monitoring with a Swan-Ganz ther-
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changes in radionuclide ejection fraction with hydrala-
zine and changes in hemodynamic variables with hy-
dralazine, either at rest or during exercise. Patients re-
sponding hemodynamically to hydralazine could not be
separated from those not responding on the basis of the
radionuclide ejection fraction at rest or changes in ejec-
tion fraction with hydralazine.
It is concluded that: l) hydralazine exerts beneficial
effects on cardiac index, stroke volume index, left ven-
tricular stroke work index and systemic vascular resis-
tance both at rest and during exercise; 2) hydralazine
therapy is associated with improvement in the radio-
nuclide left ventricular ejection fraction both at rest and
during exercise; but 3) the radionuclide ejection fraction
response to hydralazine does not correlate with and can-
not be used to predict the hemodynamic response to
hydralazine in patients with severe chronic congestive
heart failure.
modilution catheter, and as a result, necessitates hospital-
ization of such patients, usually in an intensive care unit,
and exposes them to the potential hazards of invasive mon-
itoring (7). Thus, an accurate noninvasive method of eval-
uating the hemodynamic effects of hydralazine therapy in
patients with heart failure would be valuable and could
obviate the need for hospitalization and invasive monitoring
of such patients.
Radionuclide angiography is one noninvasive approach
that has been employed with patients with heart failure to
assess the effects on left ventricular performance of various
drugs, including the vasodilator agents hydralazine (4,8),
prazosin (9-11), captopril (12,13) and nitroprusside (14).
Improvement in the radionuclide left ventricular ejection
fraction, either at rest or during exercise, in response to
vasodilators has been documented (8-11 ,13). However, the
clinical utility of radionuclide angiography in assessing the
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effect s of vasodilators in individual patient s with heart fail-
ure remain s to be defined ; it has been suggested that the
radionuclide left ventricular ejection fraction may be insen-
sitive in determining the respon se to vasodilators in patients
with a markedl y decreased ejection fraction and a dilated
left ventricle (8, 14- 16).
The present study was undertaken to investigate the ef-
fects of short-term ora! hydralazine therap y in patient s with
severe chroni c heart failure , with simultaneous hemody-
namic and radionuclide angiographic assessment at rest and
during exercise, to determine whether or not radionuclide
angiographic left ventricular ejection fraction measurement
is of value in predicting the hemod ynamic response in such
patients.
Methods
Patients. Nine patients with chronic congestive heart
failure , in New York Heart Association functional class III
or IV (17), were studied (Table I). The group included
seven men and two women , ranging in age from 36 to 68
years . The cause of the heart failure was coronary artery
disease in seven patients and was idiopathi c in two patients
(confirmed by coronary arteriography in all but one patient ).
Heart failure was of at least 3 months' durati on , stable (no
episode of pulmonary edema in the last 10 weeks) and under
treatment with stable doses of digitali s , diureti c drugs, and
in some cases, nitrate preparations. All patient s had mod-
erate to severe impairment of exercise tolerance despite this
medical therapy and musculoskeletal function was relatively
well preserved. Left ventricular ejection fraction was less
than 0 .35 by either contrast left ventriculography or radio-
nuclide angiography. Patients with myocardial infarction in
the last 3 month s and patients with primary valvular heart
disease were excluded. A grade 2/6 mitral regurgitation
murmur was heard at the time of the study in five of nine
patient s; mitral regurgitation was believed to be secondary
to left ventricular failure in these five patients. Six of the
nine patients had contrast left ventriculography within I year
of the time of the study; only one of these six patient s had
angiographically demonstrable mitral regurgitation (grade
I-II); this patient also had a mitral regurgitation murmur.
The study proto col was appro ved by the Sinai Hospital
of Detroit Medical Research Committee on Februa ry 29,
1980. Informed consent was obtained from all patient s. The
patients were hospitalized in the cardiac intensive care unit
for the duration of the study and maintained on stable sched-
ules and doses of digitali s, diuretic drugs and nitrate prep-
arations when applicable. Dietary sodium was retricted .
Hemodynamic measurements. A triple lumen Swan-
Ganz thermodilution catheter was inserted percutaneously
for determination of right atrial, pulmonary artery and pul-
monary capillary wedge pressures. Left ventricular filling
pressure was determined as either the pulmonary capillary
wedge pressure or the pulmonary artery end-diastolic pres-
sure after it was established initiall y that the pulmonary
capillary wedge and pulmonary artery end-diastolic pres-
sures were equivalent ; the method of determining left ven-
tricular filling pressure was constant in each patient. Cardiac
output was determin ed in triplicate with the thermodilution
technique. Heart rate was determined from the electrocar-
diogram simultaneously with cardiac output measurements.
Arterial blood pressure was measured using sphygmoman-
ometry of the brachial artery .
Radionuclide left ventriculography. Radionuclide left
ventricular ejection fraction was obtained by the gated equi-
librium technique, at rest and during exercise, with patients
in the supine position . A dose of 25 mCi of technetium-
99m pertechnetate dissolved in less than I ml of isotonic
saline solution was injected 30 minutes after the intravenous
Table 1. Clinical Characteri sti cs o f Nine Study Patients
Age(y r) Cause of NYHA Murmur of Mitral
Case & Sex HeaI1 Failure Class Medications Regurgitation
I 4 1M Coronary artery disease III Digoxin. furosemide , quimdine Present
2 36F Idiopath ic III-IV Digoxin , furosemide, 10 . NTG Present
ointment
3 54M Idiopathic III Digoxin, furosemide , 10 Absent
4 67M Coro nary artery disease III-IV DIgOXin, furosemide , NTG ointment Present
5 56M Coronary artery disease III Digoxin, furosemide , NTG OIntment , Present
oral NTG, quinidine
6 68F Coronary artery disease III DIgoxin, furosemide , 10 , NTG Absent
ointment
7 44M Coronary artery disease III Digoxm, furosemide, 10 , Absent
hydrochlorth iazrde , spironolactone
8 67M Corona ry artery disease III-IV Digitoxin. furosemide Present
9 65M Coronary artery disease III-IV Digoxin, furosemide , 10 , NTG Absent
ointment
F = female; 10 = isosorbide dinitrate, M = male; NTG = nitroglycerin; NYHA = New York Heart ASSOCiation
JACC Vol 2. No 5
November 1983 887-9 3
GOLDBERG ET AL
HYDRALAZINE AND EJECTION FRACTION IN HEART FAILURE
889
administration of unlabeled pyrophosphate. Ten minutes was
allowed for equilibration of the tracer in the blood pool.
Imaging was performed using a single crystal Anger gamma
scintillation camera (Ohio Nuclear Sigma 420 with a YIP
550 on-board computer) equipped with a high sensitivity,
low energy parallel holecollimator, in the left anterioroblique
projection which allowed for optimal visualization of the
interventricular septum. Data were acquired in frame mode.
Imaging at rest wasperformed until a count density of 400.000
counts/frame over the left ventricular region of interest had
been obtained and imaging during exercise was performed
until a count density of 250,000 counts/frame had been
obtained.
Data were processed by an independent observer. Back-
groundsubtraction wasperformedutilizinga paraventricular
region of interest. Left ventricular chamber edges were de-
fined using a fixed region of interest over the left ventricle
in the initial frame. End-diastolic and end-systolic images
were definedas the frames containing the largest and small-
est number of counts in this fi xed regionof interest (QMICA
program). The left ventricle in the end-diastolic frame and
in the three frames bracketing the end-systolic frame was
then manually outlined (MMICA program).
Left ventricular ejection f raction was determined f rom
the fo llowing fo rmula: Left ventricular ejection fraction =
end-diastolic counts - end-systolic counts -:- end-diastolic
counts. This process was performed at least three separate
times for each rest and exercise left ventricular ejection
fraction determination and an average value was calculated.
Study protocol. Sequential measurements at rest and
during exercise were performed at the same time of day
with the patient in the postabsorptive state. Hemodynamic
measurements were made after 15 minutes of quiet supine
rest with the patient recumbent. Radionuclide left ventric-
ular ejection fraction at rest was measured. After these de-
terminations. the patient's legs were raised and secured to
bicycle ergometer pedals (Quinton). On the initial day of
testing (control or prehydralazine), supine bicycle exercise
was begun at a work load of 200 kilopond-meters(kpm)/min
and exercise was continued to a symptom-limited maxi-
mum. The initial work load of 200 kpm/min was the max-
imal work load attained for seven of the nine patients; it
was increased to 300 kpm/min after an initial 3 minutes of
exercise at 200 kpm/min for the remaining two patients
(Table 2). During control testing, exercise was stopped in
six patients because of fatigue and in three patients because
of dyspnea. Hemodynamic variables were measured within
I minute of peak exercise. A V5 electrocardiographic lead
was monitored continuously during exercise. The radio-
nuclide left ventricular ejection fraction was measured at
peak exercise.
Patients were then returned to the cardiac intensive care
unit for continuous hemodynamic monitoring and for ini-
tiation of hydralazine therapy. A hydralazine dose of 25 mg
Table 2. Initial Exercise Test Data
Duration of Reason
Peak Work Load Exercise for Termination
Case (kpm /rmn ) (rru n ) of Exercise
I 200 6 Dyspnea
2 200 3 Dyspnea
3 300 5 Fatigue
4 300 7'/0 Fatigue
5 200 4 '1, Fatigue
6 200 3 Fatigue
7 200 4 '/ , Dyspnea
8 200 3 Fatigue
9 200 3 Fatigue
orally was given with subsequent doses administered every
6 hours and increments of 25 mg were addedto the previous
dose until maximal hemodynamic response was seen. The
maximal hydralazine dose ranged from 50 to 100mg orally
every 6 hours. Forty-eight hours after initiation of hydral-
azine therapy. patients duplicated the specific exercise pro-
tocol used on the initial day of testing (control or prehy-
dralazine). Hemodynamic variables and radionuclide left
ventricular ejection fraction were again measured at rest and
during exercise at the work load and duration of exercise
corresponding to the maximal work load and duration of
exerciseachieved on the initial day of testing. Measurements
on hydralazine were made 2 to 4 hours after the previous
hydralazine dose.
Calculated hemodynamic variables. Strokevolume in-
dex, left ventricularstroke work index and systemic vascular
resistance were calculated from the measuredhemodynamic
variables as follows: I) SYI = CO/HR/BSA, where SVI is
stroke volume index in mllbeat per rrr', CO is cardiacoutput
in rnl/rnin, HR is heart rate in beats/min and BSA is body
surfacearea in m2 . 2) LVSWI = 0.0 136 x SYI x (MLYSP
- LYFP), where LYSWI is left ventricular stroke work
index in g-rn/rrr', where MLVSP is mean left ventricular
systolic pressure in mm Hg calculated as diastolic arterial
pressure + 0.8 x pulse pressure and LYFP is the left
ventricular filling pressure as either the pulmonary capillary
wedge pressure or pulmonary artery end-diastolic pressure;
the method of determining fill ing pressure was constant in
each patient. 3) SYR = (MAP - RA/CO) x 80, where
SVR is systemic vascular resistance in dynes-s-cmr", MAP
is mean arterial pressure in mm Hg calculated as diastolic
arterial pressure + 0.33 x pulse pressure and RA is right
atrial pressure in mm Hg.
Statistical analysis. All data are presented as mean val-
ues ± I standard deviation. Comparisons between control
and hydralazine therapy, both at rest and during exercise,
were made using the paired t test. Comparisons between
rest and exercise, for both control and hydralazine therapy.
were also made using the paired t test. Relation of changes
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in left ventricular ejection fraction to changes in cardiac
index, stroke volume index, left ventricular stroke work
index and systemic vascular resistance were analyzed using
least-squares linear regression analysis. Signficance of data
was determined at the level of probability [pI < 0.05. Ar-
terial blood pressure at maximal exercise on the initial day
of testing was not obtained for one patient (Patient 8); cor-
responding left ventricular stroke work index and systemic
vascular resistance values were therefore not calculated and
Patient 8 was excluded from statistical comparisons and
linear regression analysis involving control exercise mean
arterial pressure, left ventricular stroke work index and sys-
temic vascular resistance.
Results
The maximal oral hydralazine dose was 100 mg every 6
hours in four patients, 75 mg every 6 hours in three patients
and 50 mg every 6 hours in two patients.
Hemodynamic data. Hemodynamic and radionuclide
angiographic data for the nine patients studied are sum-
marized in Table 3. Hydralazine produced significant in-
creases in cardiac index, stroke volume index and left ven-
tricularstrokework index and significant decreases in systemic
vascular resistance, both at rest and during exercise. There
were no significant changes in left ventricular fi lling pres-
sure, right atrial pressure, heart rate or mean arterialpressure
with hydralazine therapy, either at rest or during exercise.
Cardiac index, mean arterial pressure, heart rate, left ven-
tricular fi lling pressure and right atrial pressure increased
significantly from rest to exercise and systemic vascular
resistance decreased significantly from rest to exercise, both
before and during hydralazine therapy.
Ejection fraction. Hydralazine therapy was associated
with significant increases in left ventricular ejection fraction
both at rest (0.2 1 :!: 0.06 before hydralazine and 0. 26 :!:
0.07 during hydralazine therapy, p < 0.01) and during
exercise (0.2 1 :!: 0.08 before hydralazine and 0.24 :!: 0.09
during hydralazine therapy, p < 0.05) (Fig. I) . Hydralazine
therapy increased left ventricularejection fraction in all nine
patients at rest and in six of nine patients during exercise.
Changes in left ventricular ejection fraction from rest to
exercise were not statistically significant, either before or
during hydralazine therapy. There was no significant dif-
ference between control and hydralazine therapy in the in-
crease in left ventricular ejection fraction from rest to ex-
ercise (0.01 :!: 0.03 control and - 0.02 ± 0.04 hydralazine).
Correlation of ejection fraction and hemodynamic
data. There were no statistically signifi cant correlations be-
tween the percent increase in left ventricular ejection frac-
tion associated with hydralazine and either the percent in-
crease in cardiac index, stroke volume index and left ven-
tricular stroke work index or the percent decrease in systemic
vascular resistance at rest or during exercise. Similarly,
there were no statistically significant correlations between
the actual increase in left ventricular ejection fraction as-
sociated with hydralazine and either the percent increase in
cardiac index, stroke volume index and left ventricular stroke
work index or the percent decrease in systemic vascular
resistance at rest or during exercise.
Hemodynamic responders versus nonresponders. For
the purpose of data analysis, patients were categorized as
responding hemodynamically to hydralazine on the basis of
whether they manifested a 20% or greater decrease in sys-
temic vascular resistance at rest with hydralazine, or as not
responding if they manifested a less than 20% decrease in
systemic vascular resistance at rest with hydralazine (18).
Of the nine patients studied, six responded hemodynami-
cally and three did not. Responders and nonresponders could
not be adequately separated on the basis of the control left
Table 3. Hemodynam ic and Radionuclide Angiog raphic Data (mean values ± standard deviation)
Control Hydralazine Statistical Significance (p value)"
Rest Exercise Rest Exercise CR-HR CE-HE CRoCE HR-HE
CI (hters/mm per rrr' ) 1.8 :!: 0.3 2.6 :!: 0.8 2.7 :!: 0 .7 3.5 :!: 0.9 < 0.0 1 < 0.01 < 0.0 1 < 0.01
MAP (mm Hg) 93 :!: 10 103 ± 13 88 :!: 5 102 ± 8 NS NS < 0.0 1 < 0.0 1
H.R. (min- I) 85 ± 17 105 :!: 24 86 ± 16 106 = 20 NS NS < 0.0 1 < 0.0 1
LVFP (mm Hg) 21 :!: II 36 ± 8 19 ± 7 33 = 8 NS NS < 0.0 1 < 0.01
RAP (mm Hg) 5 ± 5 13 = 9 5 ± 5 13 ± 8 NS NS < 0.0 1 < 0.0 1
SVI (ml/rrr') 23 ± 8 26 ± 12 32 ± 8 34 ± 10 < 0.01 < 0.0 1 NS NS
LVSWI (g'm/m2) 29 = 12 35 ± 19 39 ± 9 45 = 14 < 0 0 1 < 0.05 NS NS
SVR (dy nes-s-crn r ") 2, 155 :!: 420 1,530 ± 348 1,447 :!: 406 1,173 :!: 230 < 0.0 1 < 0 0 1 < 0.01 < 0.05
LVEF 0.2 1 ± 0.06 0.21 ± 0.07 0.26 ± 0.08 0.24 ± 0.09 < 0.01 < 0.05 NS NS
*Patient 8 was excluded from CE-HE and CRoCE comparisons for mean artenal pressure, left ventricular stroke work index and systemic vascular
resistance.
CE = control, exercise; CI = cardiac index; CR = control, rest; HE = hydralazine. exercise; HR = hydralazine, rest; H.R. = heart rate; LVEF
= left ventricular ejection fraction; LVFP = left ventricular filling pressure; LVSWI = left ventricular stroke work index; MAP = mean arterial
pressure; RAP = right atrial pressure; SVI = stroke volume mdex: SVR = systemic vascular resistance.
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Figure 3. Distribution of percent change (%6) in left ventricu.lar
ejection fraction (LVEF) at rest (R) from control (C) to hydralazme
(H) therapy among the study patients. Closed circles represent
patients responding hemodynamically and open circles represent
patients not responding hemodynamically to hydralazine.
ventricular ejection fraction at rest (Fig. 2), or the percentage
increase in ejection fraction with hydralazine at rest (Fig.
3).
Figure 1. Left ventricular ejection fraction (LVEF) at rest (R) and
during exercise (E) in the control study and during hydralazine
therapy. Open circles and vertical bars indicate mean and range
of standard deviations, respectively.
Figure 2. Distribution of control rest (C,R) left ventricular ejec-
tion fraction (LVEF) among the study patients. Closed circles
represent patients responding hemodynamically and open circles
represent patients not responding hemodynamically to hydralazine.
Discussion
Effect of hydralazine on radionuclide ejection frac-
tion. This study confirms previous observations (1-6) re-
garding the hemodynamic effects of short-term oral hy-
dralazine in patients with chronic congestive heart failure.
At rest and during exercise, hydralazine produced an in-
crease in cardiac index that was a result mainly of an increase
in stroke volume with an associated decrease in systemic
vascular resistance. Left ventricular filling pressure was un-
affected by hydralazine, both at rest and during exercise.
The increase in the radionuclide left ventricular ejection
fraction with hydralazine, both at rest and during exercise,
in this study contrasts with results obtained by Hindman et
al. (4), who found no significant change in the radionuclide
ejection fraction (by the first-pass technique) either at rest
or during exercise with hydralazine in patients with coronary
artery disease and severe left ventricular dysfunction despite
documented hemodynamic improvement. The increase (0.05)
in the radionuclide ejection fraction at rest with hydralazine
in the present study is similar to the increase (0.08) in the
gated equilibrium ejection fraction at rest demonstrated by
Davis et al. (8) in eight patients with severe left ventricular
dysfunction after a single oral dose of hydralazine.
Variability of radionuclide ejection fraction. In the
analysis of the change in radionuclide ejection fraction as-
sociated with hydralazine therapy, the serial variability of
the radionuclide value must be taken into account. Wackers
et al. (19) demonstrated that the change in left ventricular
ejection fraction in an individual patient with an abnormal
ejection fraction must be at least 0.05 in order for that change
to be attributed to a nonrandom physiologic variation. In
the present study, five of the nine patients demonstrated an
increase in left ventricular ejection fraction of 0.05 or greater
with hydralazine at rest; only two of the nine showed an
increase in ejection fraction of 0.05 or greater with hy-
dralazine during exercise. However, with hydralazine, the
mean ejection fraction increased by 0.05 at rest and by 0.03
during exercise. Because a change in left ventricular ejection
fraction of less than 0.05 may be sufficient to demonstrate
the effect of a drug or intervention in a group of patients
as opposed to an individual patient (15,19), these changes
in mean ejection fraction may represent physiologically sig-
nificant increases related to hydralazine therapy.
Correlation of changes in ejection fraction and hemo-
dynamic variables. Although patients in this study exhib-
ited statistically significant increases in left ventricular ejec-
tion fraction both at rest and during exercise with hydralazine
therapy, there were no statistically significant correlations
between changes in ejection fraction and changes in hemo-
dynamic variables with hydralazine, either at rest or during
exercise. Furthermore, patients responding hemodynami-
cally to hydralazine could not be separated from those not
responding to hydralazine on the basis of changes in ejection
fraction with hydralazine. Davis et al. (8) described a patient
who exhibited a marked increase in cardiac index in response
to hydralazine with only a minimal increase in radionuclide
left ventricular ejection fraction; the patient had a very large
left ventricular end-diastolic volume. Firth et al. (14) re-
cently investigated the hemodynamic and radionuclide an-
giographic responses to nitroprusside in 12 patients with
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an increase in the gated equilibrium radionuclide left ven-
tricular ejection fraction of 0.05 or greater in response to
nitroprusside, while mean cardiac index in the group in-
creased from 2.1 to 2.9 liters/min per rrr', Changes in radio-
nuclide ejection fraction did not correlate with changes in
hemodynamic variables, as we demonstrated in the present
study with hydralazine. Similarly , Haq et al. (16) found no
significant change in the radionuclide ejection fraction in
response to oral vasodilators in a group of patients with
refractory congestive heart failure, despite hemodynamic
improvement.
Explanations for lack of correlation. The lack of cor-
relation between hemodynamic and radionuclide angio-
graphic responses to hydralazine therapy may reflect insen-
sitivity of the radionuclide left ventricular ejection fraction
technique in detecting small changes in patients with a di-
lated left ventricle and a markedly reduced ejection fraction
(8,14-16) . In such patients , a large increase in stroke vol-
ume related to hydralazine therapy would be associated with
a relatively small increase in ejection fraction (because of
a greatly increased left ventricular end-diastolic volume) and
this small increase could be obscured by the normal serial
variability of the radionuclide ejection fraction (19). For
instance, in a patient with a left ventricular end-diastolic
volume of 300 ml and a left ventricular ejection fraction of
0.15, the stroke volume would be 45 ml; if hydralazine
therapy produced a 33% increase in the stroke volume,
increasing it from 45 to 60 ml, the ejection fraction would
increase from 0.15 to 0.20 . This 0.05 increase in ejection
fraction would be considered at the upper limit of the ex-
pected normal serial variability.
Role of mitral regurgitation. Another possible expla-
nation for the lack of correlation between hemodynamic and
radionuclide angiographic responses is an effect of hydral-
azine on the amount of mitral regurgitation in some patients
in the study (five of the nine patients had evidence of sec-
ondary mitral regurgitation). In patients with mitral regur-
gitation , hydralazine decreases the amount of mitral regur-
gitation , increases cardiac index and stroke volume index
and decreases systemic vascular resistance without changing
the left ventricular ejection fraction (20). Of the five patients
in this study with secondary mitral regurgitation, two (Pa-
tients I and 8) manifested marked increases in cardiac index
and stroke volume index, a marked decrease in systemic
vascular resistance and an increase in radionuclide ejection
fraction of less than 0.05, with hydralazine therapy; hy-
dralazine may have increased the cardiac index and stroke
volume index in these patients by reducing the amount of
mitral regurgitation. However, in one patient (Patient 7)
without evidence of mitral regurgitation, hydralazine ther-
apy produced marked improvement in hemodynamic vari-
ables with an increase in ejection fraction of less than 0.05.
In addition, in two patients (Patients 3 and 6), hydralazine
therapy was associated with minimal improvement in hemo-
dynamic variables and an increase in ejection fraction of
0.05 or greater. Therefore, reduction in the amount of mitral
regurgitation secondary to hydralazine in some patients can-
not be the only explanation forthe observedlackof correlation.
Role of spontaneous changes in end-diastolic vol-
lime. Because a change in left ventricular end-diastolic vol-
ume with no change in stroke volume can lead to a change
in ejection fraction , it is possible that spontaneous changes
in left ventricular end-diastolic volume occurred in some
patients after hydralazine therapy had been initiated, leading
to changes in ejection fraction that were not related to the
hemodynamic effects of hydralazine. Direct measurement
of left ventricular end-diastolic volume using radionuclide
angiography may be helpful in assessing the response to
vasodilators (8,14). Left ventricular end-diastolic volume
was not measured in the present study. Finally, our study
involved nine patients; it is possible that significant corre-
lations between hemodynamic and radionuclide angio-
graphic responses to hydralazine therapy would be detected
in a larger series of patients.
Conclusion. Hydralazine exerts beneficial effects on
cardiac index, stroke volume index, left ventricular stroke
work index and systemic vascular resistance, both at rest
and during supine bicycle exercise, and is associated with
improvement in the radionuclide left ventricular ejection
fraction, both at rest and during exercise. However, in this
preliminary series, the radionuclide left ventricular ejection
fraction response to hydralazine did not correlate with and
failed to predict the hemodynamic response to hydralazine.
At present, determination of radionuclide left ventricular
ejection fraction cannot supplant invasive hemodynamic
monitoring to assess the hemodynamic effects of hydrala-
zine in individual patients with severe chronic congestive
heart failure. Radionuclide angiography may play an im-
portant role in assessing the effects of hydralazine and other
vasodilator agents in large groups of patients.
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